Professional development Vacancies

Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of February 8-11, 2021

10.03.2021 1127 views

medicinal products containing prednisolone, prednisone – bradycardia

Having reviewed the available evidence, including data provided by registration certificate holders, the PRAC agreed that registration certificate holders for medicinal products containing prednisone and prednisolone for systemic use must, within 2 months of the publication of the PRAC recommendation, submit variations to update the instructions for medical use (new text underlined):

  • in the section of the instructions for medical use “Adverse reactions”, to cardiac disorders with the frequency “not known” add bradycardia*

* after administration of high doses.

Перелік лікарських засобів, що містять prednisolone та prednisone для системного застосування і дозволені для медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 02.03.2021)

Link

https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-february-2021-prac-meeting_en.pdf